Prostate Cell News Volume 13.29 | Dec 2 2022

    0
    22








    2022-12-02 | PCN 13.29


    Prostate Cell News by STEMCELL Technologies
    Vol. 13.29 – 2 December, 2022
    TOP STORY

    Extensive Germline-Somatic Interplay Contributes to Prostate Cancer Progression through HNF1B Co-Option of TMPRSS2-ERG

    Scientists observed an enrichment of transcription factor genes including HNF1B within prostate cancer (PCa) risk-associated regions. They found a strong expression quantitative trait locus for HNF1B and multiple potential causal variants involved in the regulation of HNF1B expression in PCa.
    [Nature Communications]

    Full Article
    Tumors Are 3D. Shouldn't Your In Vitro Model Be? Learn More.
    PUBLICATIONSRanked by the impact factor of the journal

    ARID1A Loss Induces Polymorphonuclear Myeloid-Derived Suppressor Cell Chemotaxis and Promotes Prostate Cancer Progression

    Researchers showed that AT-rich interactive domain-containing proteins 1 A (ARID1A), a subunit of the SWI/SNF chromatin remodeling complex, functioned downstream of inflammation-induced IKKβ activation to shape the immunosuppressive tumor microenvironment.
    [Nature Communications]

    Full Article

    Saikosaponin a Enhances Docetaxel Efficacy by Selectively Inducing Death of Dormant Prostate Cancer Cells through Excessive Autophagy

    Saikosaponin A (SSA) was posed as a novel quiescent cancer cell (QCC)-eradicating agent by aggravating autophagy in QCCs. In combination with the current therapy, SSA had potential to improve treatment effectiveness and to prevent cancer recurrence.
    [Cancer Letters]

    Full Article

    Tautomycin and Enzalutamide Combination Yields Synergistic Effects on Castration-Resistant Prostate Cancer

    The authors reported an approach for suppressing reactivated androgen receptor (AR) signaling in the castration-resistant prostate cancer stage. A combination of tautomycin and enzalutamide synergistically inhibited cell proliferation and AR signaling in LNCaP, C4-2, and 22RV1 cells.
    [Cell Death Discovery]

    Full Article

    LNCaP-AI Prostate Cancer Cell Line Establishment by Flutamide and Androgen-Free Environment to Promote Cell Adherent

    The LNCaP-androgen dependent cell line was cultured and passaged 60 times over 16 months. The morphology of the LNCaP-androgen independent (AI) cell line was observed. Androgen receptor levels identification were detected in qRT-PCR and Western blot assay.
    [BMC Molecular and Cell Biology]

    Full Article

    Hexapeptides from Mammalian Inhibitory Hormone Hunt Activate and Inactivate Nematode Reproduction

    Reproduction had been investigated in the nematode Steinernema siamkayai, using a fermentation system supplemented with different concentrations of exogenous hexapeptides. Peptide structure-activity relationships had also been studied using prostate cancer and other mammalian cells in vitro.
    [PLoS One]

    Full Article

    Acidic Exo-Polysaccharide Obtained from Bacillus sp. NRC5 Attenuates Testosterone-DMBA-Induced Prostate Cancer in Rats via Inhibition of 5 α-Reductase and Na+/K+ ATPase Activity Mechanisms

    The anti-prostate cancer of acidic exo-polysaccharide produced from marine Bacillus sp. NRC5 was determined using 7,12-dimethylbenz-(a)-anthracene (DMBA) and DMBA-induced prostate cancer in male Sprague Dawley rats.
    [Current Microbiology]

    Full Article

    Progesterone Regulates the Endoplasmic Reticulum-Associated Degradation and Unfolded Protein Response Axis by Mimicking the Androgenic Stimulation in Prostate Cancer Cells

    The mode of action of progesterone on endoplasmic reticulum-associated degradation, unfolded protein response, and androgen receptor signaling in prostate cancer was investigated by cell culture studies using LNCaP and 22Rv1 cells.
    [Molecular Biology Reports]

    AbstractGraphical Abstract

    Synthesis of Quinoline-2-Carboxylic Acid Aryl Ester and Its Apoptotic Action on PC3 Prostate Cancer Cell Line

    Researchers synthesized an aryl ester compound from quinoline-2-carboxylic acid to evaluate its apoptotic, cell cycle blockade, and antiproliferative activity on the prostate cancer cell lines (PC3).
    [Applied Biochemistry and Biotechnology]

    Abstract
    Explore Antibodies for Epithelial Cell Markers
    REVIEWS

    Experimental In Vitro, Ex Vivo, and In Vivo Models in Prostate Cancer Research

    Preclinical prostate cancer models include standard, genetically modified and patient-derived cell lines, spheroid and organoid culture models, scaffold and hydrogel cultures, tissue slices, tumor xenograft models, patient-derived xenograft models, as well as transgenic and knockout mouse models.
    [Nature Reviews Urology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Cipla Announces Launch of Leuprolide Acetate Injection Depot (22.5mg)

    Cipla announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the US FDA based on a New Drug Application submitted under the 505(b)(2) regulatory pathway.
    [Cipla]

    Press Release

    Prostate Cancer – New Research Methods Win a Fellowship

    Dr. Pierre-Antoine Dugué was awarded the Victorian Cancer Agency Mid-Career Research Fellowship worth $681,808. The fellowships are part of an $8.5 million plan to fund new ways to detect and treat a host of cancers.
    [Monash University]

    Press Release
    FEATURED EVENT

    Cell Culture Engineering XVIII

    April 23 – 28, 2023
    Cancun, Mexico

    > See All Events

    JOB OPPORTUNITIES

    Assistant/Associate Professor – Cancer Biology

    Indiana University School of Medicine – Bloomington, Indiana, United States

    Postdoctoral Research Scientist – Computational Analysis

    Columbia University in the City of New York – New York, New York, United States

    Senior Program Associate – Science in the City

    STEMCELL Technologies, Inc. – Boston, Massachusetts, United States

    Lecturer – Cell and Developmental Biology

    Imperial College London – London, England, United Kingdom

    Lead Research Associate – Prostate Cancer

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter